Last reviewed · How we verify
HSK31679 high dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
HSK31679 high dose (HSK31679 high dose) — Haisco Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSK31679 high dose TARGET | HSK31679 high dose | Haisco Pharmaceutical Group Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSK31679 high dose CI watch — RSS
- HSK31679 high dose CI watch — Atom
- HSK31679 high dose CI watch — JSON
- HSK31679 high dose alone — RSS
Cite this brief
Drug Landscape (2026). HSK31679 high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/hsk31679-high-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab